))
The view from the top: Looking back and ahead in 2022
Manage episode 318700320 series 2925652
Content provided by Quest Diagnostics. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Quest Diagnostics or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
The COVID-19 pandemic continues to drastically disrupt the healthcare industry. At the same time, it has shone a light on the most pressing issues within its ecosystem, setting in motion the beginning of a new era of crucial changes and innovation.
In this session, Dr Alagia and Dr Wohlgemuth discuss:
- The key role played by Quest in response to the COVID-19 pandemic
- How Quest is applying its COVID-19 learnings to accelerate change across the healthcare industry
- The unique ways in which the effectiveness of the healthcare system has and can be further improved through a consumer-centric care approach, a strategy enforced at Quest
- Innovation around implementation science and strategic population health solutions available to engage consumers across all healthcare entities
About our guest
Jay G. Wohlgemuth, MD, is Senior Vice President, R&D, Medical and Chief Medical Officer for Quest Diagnostics. Based at Quest Diagnostics Nichols Institute in San Juan Capistrano, California, Dr Wohlgemuth is responsible for Research & Development, Medical Affairs, and Medical/Lab Quality. In addition, he is responsible for improving outcomes for employees who use our health benefits.
Dr Wohlgemuth has many years of experience in medical diagnostics and research and development. He rejoined Quest in 2016 from HealthTap, a health information start-up, where he served as Senior Vice President and Chief Healthcare Officer. Prior to that, he was Senior Vice President, R&D, Medical and Chief Scientific Officer with Quest. Dr Wohlgemuth originally joined us in 2009 from Genentech, where he was Director, Clinical Diagnostics, ITGR (immunology, tissue growth and repair) and Global Development Team Leader for Ocrulizumab. He also served as Vice President, R&D for VIA Pharmaceuticals and as Chief Medical Officer for the molecular diagnostics company XDx, a company he Co-Founded. Dr Wohlgemuth also served as Vice President, R&D for XDx. For his work at XDx, he was awarded Technology Pioneer 2005 at the World Economic Forum in Davos. He serves on the Board of Directors for the Personalized Medicine Coalition, Diagnostic Labs of Oklahoma, and The Anne and Henry Zarrow Charitable Foundation.
Dr Wohlgemuth earned his bachelor’s degree in biology from Harvard College and his medical degree from Stanford University School of Medicine, where he also served a fellowship in cardiovascular medicine.
------------------------------
Quest Diagnostics empowers people to take action to improve health outcomes. Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors, and improve healthcare management. Quest Diagnostics annually serves 1 in 3 adult Americans and half the physicians and hospitals in the United States, and our 47,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives.
More information is available at www.QuestDiagnostics.com
16 episodes
Share
